We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Clovis Oncology may have ditched development of cancer treatment rociletinib years ago, but the drug is going to cost the company, its CEO and its former CFO more than $20 million.